# Prolonged Clinical Follow-up of OPTIMA-5

Study · id `cardio:ct-nct05649696` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05649696](<https://clinicaltrials.gov/study/NCT05649696>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05649696

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.

## Technical summary

Registry record NCT05649696. Randomized; triple masking; primary purpose treatment. Start 2021-10-29 (actual); primary completion 2023-09-14 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 210 participants (enrolled count; ClinicalTrials.gov record NCT05649696, source copy `cardio:ctgov-nct05649696-2024-09-25`, retrieved 2026-10-26)
- Started: 2021-10-29 (actual) (ClinicalTrials.gov record NCT05649696, source copy `cardio:ctgov-nct05649696-2024-09-25`, retrieved 2026-10-26)
- Primary completion: 2023-09-14 (actual) (ClinicalTrials.gov record NCT05649696, source copy `cardio:ctgov-nct05649696-2024-09-25`, retrieved 2026-10-26)
- Completion: 2023-10-01 (actual) (ClinicalTrials.gov record NCT05649696, source copy `cardio:ctgov-nct05649696-2024-09-25`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05649696, source copy `cardio:ctgov-nct05649696-2024-09-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05649696-2024-09-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Prolonged Clinical Follow-up of OPTIMA-5
- Condition: ST-segment Elevation Myocardial Infarction (STEMI)
- Intervention (Drug): Recombinant Staphylokinase
- Intervention (Drug): Normal Saline
- Lead sponsor: The First Affiliated Hospital with Nanjing Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: The First Affiliated Hospital with Nanjing Medical University (`cardio:org-the-first-affiliated-hospital-with-nanjing-medical-898271`)

## Provenance

Content hash: 651e444b6e0c7c6255560b1574df3be86776a9b7dbef825b81bb6997a3ce8bf1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
